Literature DB >> 30668742

Antiretroviral Treatment of Acute HIV Infection Normalizes Levels of Cerebrospinal Fluid Markers of Central Nervous System (CNS) Inflammation: A Consequence of a Reduced CNS Reservoir?

Magnus Gisslén1, Peter W Hunt2.   

Abstract

Entities:  

Year:  2019        PMID： 30668742      PMCID： PMC6833976          DOI： 10.1093/infdis/jiz031

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  32 in total

1.  Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy.

Authors:  Aylin Yilmaz; Bo Svennerholm; Lars Hagberg; Magnus Gisslén
Journal:  Antivir Ther       Date:  2006

Review 2.  HIV-1 target cells in the CNS.

Authors:  Sarah B Joseph; Kathryn T Arrildt; Christa B Sturdevant; Ronald Swanstrom
Journal:  J Neurovirol       Date:  2014-09-19       Impact factor: 2.643

3.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Authors:  Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

Review 4.  Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection.

Authors:  Peter W Hunt; Sulggi A Lee; Mark J Siedner
Journal:  J Infect Dis       Date:  2016-10-01       Impact factor: 5.226

5.  Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection.

Authors:  Lars Hagberg; Paola Cinque; Magnus Gisslen; Bruce J Brew; Serena Spudich; Arabella Bestetti; Richard W Price; Dietmar Fuchs
Journal:  AIDS Res Ther       Date:  2010-06-03       Impact factor: 2.250

6.  Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection.

Authors:  Elizabeth Sinclair; Rollie Ronquillo; Nicole Lollo; Steven G Deeks; Peter Hunt; Constantin T Yiannoutsos; Serena Spudich; Richard W Price
Journal:  J Acquir Immune Defic Syndr       Date:  2008-04-15       Impact factor: 3.731

7.  Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatment.

Authors:  Gustaf Ulfhammer; Arvid Edén; Åsa Mellgren; Dietmar Fuchs; Henrik Zetterberg; Lars Hagberg; Staffan Nilsson; Aylin Yilmaz; Magnus Gisslén
Journal:  AIDS       Date:  2018-09-24       Impact factor: 4.177

8.  Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial.

Authors:  Jason V Baker; Shweta Sharma; Birgit Grund; Adam Rupert; Julia A Metcalf; Mauro Schechter; Paula Munderi; Inka Aho; Sean Emery; Abdel Babiker; Andrew Phillips; Jens D Lundgren; James D Neaton; H Clifford Lane
Journal:  Open Forum Infect Dis       Date:  2017-11-28       Impact factor: 3.835

9.  Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial.

Authors:  Jason V Baker; Shweta Sharma; Amit C Achhra; Jose Ignacio Bernardino; Johannes R Bogner; Daniel Duprez; Sean Emery; Brian Gazzard; Jonathan Gordin; Greg Grandits; Andrew N Phillips; Siegfried Schwarze; Elsayed Z Soliman; Stephen A Spector; Giuseppe Tambussi; Jens Lundgren
Journal:  J Am Heart Assoc       Date:  2017-05-22       Impact factor: 5.501

10.  Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment.

Authors:  Arvid Edén; Thomas D Marcotte; Robert K Heaton; Staffan Nilsson; Henrik Zetterberg; Dietmar Fuchs; Donald Franklin; Richard W Price; Igor Grant; Scott L Letendre; Magnus Gisslén
Journal:  PLoS One       Date:  2016-06-13       Impact factor: 3.240
View more
  2 in total

1.  Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression.

Authors:  Magnus Gisslen; Sheila M Keating; Serena Spudich; Victor Arechiga; Sophie Stephenson; Henrik Zetterberg; Clara Di Germanio; Kaj Blennow; Dietmar Fuchs; Lars Hagberg; Philip J Norris; Julia Peterson; Barbara L Shacklett; Constantin T Yiannoutsos; Richard W Price
Journal:  PLoS One       Date:  2021-05-13       Impact factor: 3.240

2.  No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approach.

Authors:  Jasmini Alagaratnam; Wolfgang Stöhr; Jamie Toombs; Amanda Heslegrave; Henrik Zetterberg; Magnus Gisslén; Sarah Pett; Mark Nelson; Amanda Clarke; Nneka Nwokolo; Margaret A Johnson; Maryam Khan; Tomas Hanke; Jakub Kopycinski; Lucy Dorrell; Julie Fox; Sabine Kinloch; Jonathan Underwood; Matthew Pace; John Frater; Alan Winston; Sarah Fidler
Journal:  J Virus Erad       Date:  2021-09-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.